CP
ABBV icon

Clayton Partners’s AbbVie ABBV Stock Holding History

Clayton Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.59M Buy
18,246
+50
+0.3% +$10.8K 3.02% 12
2026
Q1 		$3.96M Buy
18,196
+65
+0.4% +$14.4K 2.88% 18
2025
Q4 		$4.14M Sell
18,131
-207
-1% -$47.2K 2.99% 14
2025
Q3 		$4.25M Sell
18,338
-34
-0.2% -$6.92K 3.22% 10
2025
Q2 		$3.41M Sell
18,372
-1,867
-9% -$347K 2.87% 13
2025
Q1 		$4.24M Buy
20,239
+260
+1% +$50.5K 3.69% 9
2024
Q4 		$3.55M Sell
19,979
-101
-0.5% -$18.6K 2.46% 18
2024
Q3 		$3.97M Sell
20,080
-164
-0.8% -$30.6K 2.86% 13
2024
Q2 		$3.47M Sell
20,244
-227
-1% -$37.6K 2.79% 15
2024
Q1 		$3.73M Sell
20,471
-3,913
-16% -$674K 3.17% 11
2023
Q4 		$3.78M Buy
24,384
+19
+0.1% +$2.77K 3.06% 14
2023
Q3 		$3.63M Buy
24,365
+584
+2% +$85.7K 3.09% 14
2023
Q2 		$3.2M Sell
23,781
-157
-0.7% -$23K 2.77% 14
2023
Q1 		$3.82M Buy
23,938
+68
+0.3% +$10.4K 3.71% 9
2022
Q4 		$3.86M Buy
23,870
+542
+2% +$83.1K 3.65% 10
2022
Q3 		$3.13M Buy
23,328
+78
+0.3% +$11.2K 3.53% 9
2022
Q2 		$3.56M Sell
23,250
-44
-0.2% -$6.72K 3.84% 10
2022
Q1 		$3.78M Buy
23,294
+807
+4% +$117K 3.18% 12
2021
Q4 		$3.04M Buy
22,487
+330
+1% +$39K 2.65% 13
2021
Q3 		$2.39M Sell
22,157
-8
-0% -$914 2.29% 21
2021
Q2 		$2.5M Buy
22,165
+772
+4% +$86.9K 2.1% 21
2021
Q1 		$2.31M Buy
+21,393
New +$2.29M 2.24% 19

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clayton Partners's ABBV Position: Q2 2026 in Review

Clayton Partners increased its AbbVie (ABBV) stake by 0.27% in Q2 2026, buying an estimated $10.8K and bringing the position to 18,246 shares worth $4.59M. The position accounts for 3.02% of the portfolio, ranked #12.

Clayton Partners first reported a position in ABBV in Q1 2021 and has held it in 22 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Clayton Partners held 18,246 shares of AbbVie worth $4.59M as of Q2 2026.
  • Clayton Partners bought 50 AbbVie shares in Q2 2026, an estimated $10.8K.
  • AbbVie made up 3.02% of Clayton Partners's portfolio in Q2 2026, its #12 holding.
  • Clayton Partners first reported a position in AbbVie in Q1 2021 and has held it in 22 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Clayton Partners's 13F filing for Q2 2026, filed 14 Aug 2026.